2023環境、社會及管治報告
*僅供識別
(於中華人民共和國註冊成立的股份有限公司)股份代號: 9995
榮昌生物製藥(煙台)股份有限公司RemeGen Co., Ltd.*
1. 4
1.1. 4
1.2. ESG5
1.3. 6
2. 7
2.1. 7
2.1.1. 7
2.1.2. 8
2.2. ESG10
2.2.1. ESG10
2.2.2. 10
2.2.3. 11
2.3. 11
2.3.1. 12
2.3.2. 13
2.3.3. 14
3. 16
3.1. 16
3.1.1. 16
3.1.2. 17
3.1.3. 20
3.1.4. 21
3.2. 21
3.2.1. 21
3.2.2. 26
3.2.3. 28
3.3. 32
3.3.1. 32
3.3.2. 33
3.3.3. 34
4. 37
4.1. 37
4.1.1. 37
4.1.2. 39
4.1.3. 43
4.2. 46
4.2.1. 46
4.2.2. 50
4.2.3. 52
4.2.4. 55
4.2.5. 61
5. 62
5.1. 62
5.1.1. 62
5.1.2. 64
5.1.3. 68
5.2. 70
5.2.1. 70
5.2.2. 72
5.3. 76
6. 77
6.1. ESG77
6.2. 83
2023
ESG?
2023111231??
?
ESGGRI(GRI standards)(MSCI)?
??
https://www.remegen.cn/index.php?v=listing&cid=31#xxpl
2023
(ESG)
ESGESGESGESGESGESG
ESGESGESGESGESGESGESG
ESG2023ESGESGESGESGESGESG
2023ESG2024426
2023
1.
1.1.
09995.HK688331.SH
2008
(ADC)(first-in-class)(best-in-class)
2023
1.
1.2. ESG
? ISO 14001ISO 50001? 20202025
0.6%202520203.1%???? 6ISO 9001? 2217
17,400? 1,30836.18%? ISO 45001? 273.15? 100%100%?? 139?? 391,900100%
2023
1.
1.3.
Biotech
(ADC)20222020TOP30
2023
2023
2.
ESG
2.1.
2.1.1.
2023942
2023
2.
2.1.2.
?????
?????
2023
2.
??????
2023
2.
2.2. ESG
ESG
2.2.1. ESG
ESGESGESG
ESGESG
2.2.2.
2023
2023
2.
2.2.3.
2023ESG
2023
2023ESG8102
社會議題環境議題公司管治議題
對利益相關方的重要性
對企業發展的重要性
高度重要議題
中度重要議題低度重要議題
合規風險管理
員工培訓與發展員工福利保障供應商可持續管理
水資源節約
能源節約原材料使用反腐敗合法僱傭
排放物管理廢棄物管理員工健康與安全客戶服務保障產品質量安全產品研發創新
知識產權保護藥品可得性負責任營銷
社會公益行動
行業發展貢獻
2023ESG
2.3.
2023
2.
2.3.1.
56132
0535-6383102shenjichu@remegen.com
20233-515
2023
2.
2.3.2.
2023
391,900100%
2023
2.
2.3.3.
IT744727314
ISO 9001ISO 14001ISO 45001OHSAS 18001
GMP
2023
2.
2023
3-4ESG
EHS
2023
2023ISO
ISO
ISO 9001160ISO 1400190ISO 4500165
2023
3.
3.1.
3.1.1.
2010(FDA)(EMA)(NMPA)GMP
(USP)(EP)/
(edoc2)(GMP)GMP20232,182QA156QC762MFGRMM946RMM42ENG181IT95
(CAPA)GMP
2023
3.
(PQE)2023501
3.1.2.
(CQA)(QTPP)
3CQA
(CAPA)
2023
3.
1FDA
(cQML)(SMP)(SOP)
2023
3.
SUS1082
1,573E&L80NMPAFDAEMEA
&SUS//
2023
244872
2023
3.
3.1.3.
2023
ISO 90012023(CNAS)
CNAS
2023
3.
3.1.4.
edoc2
GMP2023GMP2023221717,400
3.2.
3.2.1.
(GMP)
2023221,308
36.18%2023
1,306,306,79433%
edoc2(ECM)
2023
3.
20231ADC
1RC148
202312ADC
202310
RC148
1-21-2RC1481I
2023
3.
(ADC)
/
/(DS)/(DP)GMP
(RC18)RC28
ADC
GMPGMP
TOPOiADC
ADCPK/PD
(HiBody)
(HiBody)
(ADC)
2023
3.
20231122BLyS/APRIL
?
(CDE)II/III
Journal of Clinical Oncology
ADCFDAJournal of Clinical OncologyJCO
C005&C009
2023
3.
2023BLA 1IND/CTA 25
233RC18G00112IND
IND/17/161
(CDE)12(FDA)1(EMA)1
1RC88fast track2RC18 MGRC88
? SLE 390? pSS 32023(FDA)
SLE 3RC18? RC198 14
? Seagen/PfizerRC48
2023
3.
202320232023
/ADC
XDaybreak 2023
2023818XDaybreak 2023
AIIT
3.2.2.
2023
2023
3.
2023
2023
202331
2023
3.
202358
2023
2023
3.2.3.
2023
3.
?????? M10?
????
2.0
???
?? ICHE6(R2)? ICHE3? ICHE8(R1)? ICHE9?
2023
3.
2023
3.
3R
GB/T 35892-2018GB/T 42011-2022
BSL-2
GB 14925-2010
3R(Replacement)(Reduction)(Refinement)
BSL-2bio-safety level laboratory-2II
2023
3.
3.3.
3.3.1.
(GVP)
2023
2023
3.
20231
3.3.2.
2023
SOP
2023
3.
2023IWRSEDC
3.3.3.
2023
3.
2023
3.
&P4 China20232023ADC202520234
QACDE
2023
4.
4.1.
4.1.1.
ISO 45001&ISO 14001EHS
EHS(EHS)EHS
EHS
EHS
2023
4.
2023ISO 45001
ISO 450012
(EHS)
EHS
ISO 45001
2023
4.
4.1.2.
2023
273.15
0000
‰ 2023
2023
2023
2023
4.
53475
2023261,015
2023
4.
2023
2023
2023
4.
GMPGMPQC
424100%
202120222023
%000
8112854
2023132100%
2023
4.
4.1.3.
EHS202337
12,765821,0791,079
2023
4.
2023
2023
3,400
2023
4.
2023
4.
2023
4.2.
4.2.1.
TCFDTask Force on Climate-related FinancialDisclosures
2023
4.
2023
4.
2023
4.
? 20202025
0.6%202520203.1%? 202520300.4%20353%
202120222023
0095.7722,183.0439,551.5570,100.0022,183.0439,551.5570,195.76/ 0.160.520.65
20232022
2023
4.
4.2.2.
2023ISO 14001
ISO 140012023
2023
4.
2023
2023
2023
4.
20236
4.2.3.
2023
4.
2023
SBR++++
600/1,700/1,300/
202120222023
187,229.0096,792.00224,221.86COD15.5613.5321.16
1.761.783.13
(VOC)
+400/K
202120222023
168,900,000193,040,000167,004,000VOC
0.230.140.02784
2022K300m
/2023K700m
/202213-14
2023VOC2022
2023
4.
HW01HW02
HW06HW08HW49
EP
2023
4.
MMAE
202120222023
77.74125.87141.25
/0.000550.00160.0013
202120222023
17.325.250/0.000120.000330.00046
4.2.4.
2023
4.
ISO 50001
ISO 50001
? 202520352%
2023
4.
36%
2023
4.
4420
2023? C/D6,000?
25,000?
236,000? 33,000? 16,000/? PQ
645,000
2023
4.
2023
202120222023
36,344,60944,574,702.866,055,006.483,596.55125,868.86290,390.9
//28.20//137,344.839,877.5618,265.16/0.050.130.17
202320222%
202320222023106206305QC
20232022
2023
4.
202320222023106206305QC20232022
2023
335s620s4,200/
12562,367/
RO202352,000
90%
202120222023
300,600407,176.67694,042.91
25,90026,00052,000/2.115.36.35
202344.35
0.41/
2023
4.
2023???????
4.2.5.
2023
edoc2
2023
5.
5.1.
5.1.1.
202312313,775
202213.3%
3,561/214
2023
5.
2023
20222023
3,3323,7751,5551,1213,3313,561/1214
1,5611,6741,7712,101301,5431,46630-501,7402,254504955
1401636047432,5882,8693,3203,7601215%17.727.0%19.734.9%8.520.730%8.728.630-50%8.926.350%0.110.9
%17.727.0%026.7
2023
5.
20233-5
????
5.1.2.
A40
213.4
100%
2023
5.
20233.8
2023
2023
5.
2023
2023
5.
2023926
20231,816.03
2023
5.
5.1.3.
95%
2023
5.
2023
2022202372022
2022
2023
5.
5.2.
5.2.1.
2023
5.
20234
2023
5.
5.2.2.
2023
5.
/
/
/
3,29356,4642023
20222023
2,1803,2931,10056,464
20222023
%65.487.2%70.745.2%60.854.8%75.02.6%128.321.3%50.276.1
0.5017.1
0.3617.6
0.3116.8
0.389.8
0.6524.0
0.2515.5
2023
2023
5.
2023
96%
2023
5.
2023
1,04346424391
2023
5.
2023
6562GCP31PMP2
5.3.
2023
2023
6.
6.1. ESG
A1
(a)(b)
P49P52-54
A1.1P52A1.212
P49A1.3
P55A1.4
P55A1.5P51A1.6
P54-55
2023
6.
A2
P56A2.1/
P59A2.2P60A2.3P56-58A2.4
P60A2.5P60A3
P50-P51A3.1
P50-52
A4
P46-48A4.1P46-48
2023
6.
B1
(a)(b)
P62
B1.1P63B1.2P63
B2
(a)(b)
P37-39
B2.1P42B2.2P42B2.3P39-42
2023
6.
B3
P72-73B3.1P73B3.2P73
B4
(a)(b)
P62
B4.1P62B4.2P62
2023
6.
B5
P14B5.1P14B5.2
P14-15B5.3
P14-15B5.4
P14-15
B6
(a)(b)
P16
B6.1P19B6.2P33B6.3P26-27B6.4P19-20B6.5P33-34
2023
6.
B7
(a)(b)
P12
B7.1
P12B7.2P12B7.3P13
B8
P76B8.1P76B8.2P76
2023
6.
6.2.